We’re Hiring! View Open Positions

Archives

Last 20 Posts

 
  1. Enzyvant Receives FDA Approval for RETHYMIC® (allogeneic processed thymus tissue-agdc), a One-Time Regenerative Tissue-Based Therapy for Pediatric Congenital Athymia
  2. Enzyvant Announces Plans to Expand Regenerative Medicine Manufacturing Capabilities
  3. Sumitovant and Enzyvant Appoint Bill Symonds, CEO of Altavant Sciences, as Interim Chief Executive Officer of Enzyvant
  4. Enzyvant Appoints Johanna Rossell as Chief Commercial Officer
  5. Enzyvant Announces First-Ever Data on Burden of Illness and Costs of Supportive Care for Pediatric Congenital Athymia
  6. Enzyvant Announces Publication of Positive Clinical Data in Pediatric Patients with Congenital Athymia Treated with Investigational RVT-802 (allogeneic processed thymus tissue-agdc)
  7. Aceragen Launches with Acquisition of Enzyvant‘s Investigational Therapy for Farber Disease and $35 Million Product Financing with NovaQuest
  8. ENZYVANT Resubmits Biologics Licensing Application (BLA) to FDA for RVT-802 for Pediatric Congenital Athymia
  9. Sumitomo Dainippon Pharma Completes the Formation of the Strategic Alliance with Roivant Sciences
  10. Sumitomo Dainippon Pharma and Roivant Sciences Sign Definitive Agreement for Strategic Alliance
  11. Enzyvant Appoints Jeb Ledell as Chief Operating Officer
  12. Enzyvant Announces FDA Acceptance of Biologics License Application (BLA) and Priority Review Status for RVT-802, a Novel Investigational Tissue-Based Regenerative Therapy for Pediatric Congenital Athymia
  13. Enzyvant’s Investigational Regenerative Treatment (RVT-802) for Congenital Athymia to be Discussed in Symposium, Platform Presentation and Poster Session at Clinical Immunology Society Meeting
  14. Enzyvant Appoints Industry Veteran Rachelle Jacques as Chief Executive Officer
  15. Enzyvant Announces Initiation of RVT-802 Rolling BLA Submission for the Treatment of Complete DiGeorge Anomaly
  16. Enzyvant Receives FDA Rare Pediatric Disease Designation for Investigational Therapy RVT-802
  17. Enzyvant Receives FDA Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy Designation for Investigational Therapy RVT-802
  18. Rare Disease Day
  19. RARE in the Square
  20. Enzyvant to Develop Novel Biologic Therapy for Complete DiGeorge Syndrome

By Month

 

Contact us for more information